PS
ACAD icon

Principal Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

Principal Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,043
Closed -$22.3K – 1362
2025
Q3 		$22.3K Buy
1,043
+454
+77% +$10.7K ﹤0.01% 2358
2025
Q2 		$12.7K Buy
589
+576
+4,431% +$10.7K ﹤0.01% 2521
2025
Q1 		$239 Hold
13
– – ﹤0.01% 3439
2024
Q4 		$239 Buy
+13
New +$210 ﹤0.01% 3434

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Principal Securities's ACAD Position: Q4 2025 in Review

Principal Securities sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 1,043 shares — an estimated $22.3K sold.

Principal Securities first reported a position in ACAD in Q4 2024 and held it in 4 quarters. The position peaked at $22.3K in Q3 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Principal Securities reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 1,043 Acadia Pharmaceuticals shares in Q4 2025, an estimated $22.3K.
  • Principal Securities first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Principal Securities's Acadia Pharmaceuticals position peaked at $22.3K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.